Dovitinib (Not yet branded)
Targeted Therapy
Description
Dovitinib is a multi-targeted receptor tyrosine kinase inhibitor that has been evaluated for maintenance therapy in colorectal cancer patients following standard treatment. This oral small molecule drug simultaneously blocks multiple growth factor receptors involved in tumor progression and angiogenesis. In colorectal cancer, dovitinib has been studied as a maintenance therapy option for patients with advanced disease, particularly in combination with biomarker-guided treatment approaches.
Mechanism of Action
Dovitinib inhibits multiple receptor tyrosine kinases including fibroblast growth factor receptors (FGFR1, FGFR2, FGFR3), vascular endothelial growth factor receptors (VEGFR1, VEGFR2, VEGFR3), platelet-derived growth factor receptor beta (PDGFR ), and FLT3. By blocking these signaling pathways, the drug disrupts tumor cell proliferation, survival signals, and the formation of new blood vessels that tumors require for growth and metastasis.
Molecular Targets
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
Quick Info
| Brand Name | Not yet branded |
| Category | Targeted Therapy |
 Status | Experimental |
 EMA Status | Experimental |
 Spain Access | Not available |
| Administration | Oral |
| Clinical Trials | 2 |
Related Medications
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.